Title:Nano Diosgenin Abates DMBA Induced Renal and Hepatic Toxicities:
Biochemical and Histopathological Evaluation on the Breast Cancer Model
Volume: 19
Issue: 4
Author(s): Manobharathi Vengaimaran, Kalaiyarasi Dhamodharan and Mirunalini Sankaran*
Affiliation:
- Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar-608002,
Tamilnadu, India
Keywords:
Mammary cancer, diosgenin, nanoencapsulation, liver marker enzymes, renal biomarkers, total cholesterol.
Abstract:
Background: Nature-based pharmaceuticals are now becoming an integral aspect of
toxic-free healthcare therapies. Diosgenin (DN), a unique phyto steroidal sapogenin, seems to be
explicitly employed as a core ingredient in countless traditional and patented Chinese medicines
owing to its epic multilayered therapeutic treasure.
Objective: The prime intent of the current study was to probe the hepato- and nephro- ameliorating
the impact of Diosgenin encapsulated chitosan nanoparticles (DN@CS-NPS) on 7,12-
dimethylbenz(a)anthracene (DMBA) mediated rat mammary oncogenesis.
Methods: A single dosage of DMBA (25 mg/kg body weight) was injected to induce breast cancer.
Oral administration of DN (10 mg/kg body weight) and DN@CS-NPS (5 mg/kg body weight)
was used to medicate DMBA administered tumor-bearing rats just after the emergence of a tumor.
Following the experimental duration, biochemical and histopathological (H&E) analyses have
been carried out.
Results: Here, we noticed that there is an escalated level of liver and kidney biomarkers, phase-I
detoxification enzymes, lipid peroxidative marker, total cholesterol (TC), phospholipids (PL),
triglycerides (TG), and free fatty acids (FFA), low-density lipoprotein (LDL), very low-density
lipoprotein (VLDL), total lipase (TL) as well as diminished levels of phase – II detoxification enzymes,
enzymatic and non-enzymatic antioxidants, high-density lipoprotein (HDL), lipoprotein
lipase (LPL) and lecithin acyltransferase (LCAT) in the plasma, liver and kidney tissues of
DMBA-induced rats with renal and hepatic histopathological alterations. Conversely, oral treatment
of DN@CS-NPS substantially reduced their tiers to near-normal levels.
Conclusion: Thus, our observations suggested that DN@CS-NP is an impactful hepato- and
nephro- therapeutic agent that might have a significant influence on breast cancer over free DN.